Scholars Central

Conference abstractPublished 26 Aug 2013

Ampi-109, a novel Vitamin D analog for androgen-insensitive prostate and renal cancer

Authors: Rahul Ray

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Non-classical properties of 1α, 25-dihydroxyvitamin D3 (1, 25(OH) 2D3 ), the vitamin D hormone includes inhibition of proliferation and differentiation of malignant cells raising its potential as a cancer therapeutic agent. But, therapeutic use of 1, 25(OH) 2D3 in various cancers has been limited by the risk of toxicity related to hypercalcemia and hypercalciuria at clinically useful doses, thereby setting the ground for developing 1, 25(OH) 2D3 -analogs with low toxicity and potent anti-proliferative activity. Our laboratory has developed AMPI-109, a novel alkylating analog of 1, 25(OH) 2D3 . We observed that AMPI-109 is a significantly stronger anti-proliferative agent than 1, 25(OH) 2D3 in several prostate and renal cancer cells. But, AMPI-109 did not inhibit the growth of normal prostate and renal cells. We noted that AMPI-109 is a significantly superior inhibitor of renal cancer cell growth than afinitor, axitinib, sorafenib and sunitinib, the currently approved drugs for renal cell carcinoma. Most significantly, AMPI-109 strongly inhibited tumor-growth in mouse models of human androgen-insensitive prostate and renal cancers, demonstrating the potential of AMPI-109 as a therapeutic agent in these malignancies. AMPI-109 was initially developed as an affinity alkylating agent for nuclear vitamin D receptor, the transcriptional factor responsible for the cellular actions of 1,25(OH) 2D3 . But, our recent studies demonstrate that the anti-proliferative action of AMPI-109 is independent of VDR in prostate and kidney cancer cells, setting AMPI-109 apart from all known analogs of 1,25(OH) 2D3 . In this presentation we will delineate these results and discuss the potential of AMPI-109 as an effective and safe therapeutic agent for androgen-insensitive prostate and renal cancers.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Endocrinology & Metabolic Syndrome.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalEndocrinology & Metabolic Syndrome
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Rahul Ray”